Fundraising Fox
Lodestone Biomedical
Lebanon, US · Founded 2015 · Delaware corporation
Find your way into Lodestone Biomedical
Sign up to see every warm intro you have to Lodestone Biomedical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lodestone Biomedical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lodestone Biomedical develops biosensing and monitoring tools for the tumor microenvironment in preclinical cancer research models, enabling detection of immune response during early-stage drug discovery. Its research-use-only products and services serve drug development researchers conducting preclinical studies.
Founders & leadership
Lodestone Biomedical was founded in 2015 by Solomon Diamond.
Reported raises · per SEC filings
Form D private placements$1.2M disclosed across 4 rounds · 2017–2025
▶$75KraisedJul 2025 · 1 investors · BiotechnologyRule 506(b)
- Solomon DiamondExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $75K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$450KraisedDec 2021 · 6 investors · BiotechnologyRule 506(b)
- Solomon DiamondExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $450K
- First sale
- Dec 2021
- Incorporated
- Limited Liability Company, New Hampshire
- Federal exemptions
- 06b
▶$110KraisedApr 2020 · 3 investors · BiotechnologyRule 506(b)
- Solomon DiamondExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $110K
- Minimum investment
- $5K
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, New Hampshire, 2015
- Federal exemptions
- 06b
▶$550KraisedJul 2017 · 7 investors · BiotechnologyRule 506(b)
- Solomon DiamondExecutive Officer, Director
- Lidia ValdesExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $550K
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- Jul 2017
- Incorporated
- Limited Liability Company, New Hampshire, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $400K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Lodestone Biomedical do?
- Lodestone Biomedical develops biosensing and monitoring tools for the tumor microenvironment in preclinical cancer research models, enabling detection of immune response during early-stage drug discovery. Its research-use-only products and services serve drug development researchers conducting preclinical studies.
- Who founded Lodestone Biomedical?
- Lodestone Biomedical was founded by Solomon Diamond in 2015.
- How much funding has Lodestone Biomedical raised?
- Lodestone Biomedical has disclosed $1.2M raised across 4 rounds.
- Where is Lodestone Biomedical headquartered?
- Lodestone Biomedical is headquartered in Lebanon, US.